Research and Markets (http://www.researchandmarkets.com/research/9347b9/the_future_of_card)
has announced the addition of the "The
Future of Cardiovascular Diseases Therapeutics - Market Forecasts to
2015, Competitive Benchmarking, Product Pipeline and Deals Analysis"
report to their offering.
"The
Future of Cardiovascular Diseases Therapeutics - Market Forecasts to
2015, Competitive Benchmarking, Product Pipeline and Deals Analysis"
provides insights on the cardiovascular market potential, actual sales,
actual volume and price forecasts to 2015. The report also delves deep
into the cardiovascular market potential in various indications such as
hypertension, dyslipidemia and thrombosis. The report also provides
insights into the cardiovascular R&D pipeline. The report also
elucidates the cardiovascular competitive landscape including
benchmarking of leading companies. Finally, the key trend analysis on
mergers and acquisitions, and licensing agreements involving
cardiovascular was also provided.
Patent Expiries Coupled with Generic Competition are Negatively
Impacting the Market.
The global cardiovascular therapeutics market was valued at $76 billion
in 2008 and expected to fall to $67 billion with a CAGR of -1.7% by
2015. Approximately 127 million patients received pharmacological
treatment for cardiovascular diseases. The patient volume appears to be
increasing at a slow rate. In addition, the average annual cost of
therapy for the cardiovascular diseases therapeutic area appears likely
to increase at a gradual rate over the next 1-2 years with an expected
price decline from 2011 onwards. As a result, the cardiovascular
diseases market value is going to see a decline over the time period
2008-2015.
Unmet Need in Cardiovascular Therapeutics Market is Low, Except for
Antithrombosis Indication
Cardiovascular diseases disorders such as hypertension and dyslipidemia
are currently one of the most explored therapeutic areas. The market is
filled with several drug classes that are both safe and effective. There
is not any serious unmet need for these indications. The antithrombotic
market is in need of an effective replacement for Warfarin. New oral
thrombin and factor Xa inhibitors are expected to produce more
predictable anticoagulant responses than Warfarin, eliminating the need
for regular monitoring and dose adjustments.
Increasing Cost of Novel Drug Development, Declining Market Size and
Shrinking Target Population are Forcing Top Companies to Exit the
Segment.
Pfizer, the leader in cardiovascular diseases has decided to exit from
this segment due to its failure to develop any novel drug coupled with
concerns over patent expiries. The growth of generics could be one
reason because generic producers spend nothing on R&D thereby hampering
the innovative drug discovery process. In licensing, mergers and
acquisitions and partnerships are some of the strategies commonly used
by the pharmaceutical companies to overcome the drying of their pipeline
product resourcess.
Pfizer has entered into an agreement with two Indian companies,
Aurobindo Pharmaceuticals and Claris Lifesciences, boosting its pipeline
resource with 60 new products
Scope
The scope of this report includes: